Genscript Bio announced that the Board of Directors meeting will be held on Friday, August 9, 2024, where they will consider and approve the mid-term performance report until June 30, 2024, as well as its release. The meeting will also consider whether to distribute mid-term dividends. The company is chaired and held by Executive Director Meng Jiangge, with Executive Directors Dr. Zhang Fangliang, Ms. Wang Ye, and Dr. Zhu Li and Non-Executive Director Dr. Wang Luquan. Mr. Dai Zumian, Mr. Pan Jiu'an, Mr. Zhang Yaoliang, and Dr. Shi Chenyang serve as independent-non-executive directors. The specific agenda of the meeting includes reviewing and approving the mid-term performance report and deciding on the distribution of mid-term dividends.

Genscript Bio announced that the Board of Directors meeting will be held on Friday, August 9, 2024, where they will consider and approve the mid-term performance report until June 30, 2024, as well as its release. The meeting will also consider whether to distribute mid-term dividends. The company is chaired and held by Executive Director Meng Jiangge, with Executive Directors Dr. Zhang Fangliang, Ms. Wang Ye, and Dr. Zhu Li and Non-Executive Director Dr. Wang Luquan. Mr. Dai Zumian, Mr. Pan Jiu'an, Mr. Zhang Yaoliang, and Dr. Shi Chenyang serve as independent-non-executive directors. The specific agenda of the meeting includes reviewing and approving the mid-term performance report and deciding on the distribution of mid-term dividends.